Connor, Clark & Lunn Investment Management Ltd. Ngm Biopharmaceuticals Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$1.17 - $1.92 $114,703 - $188,231	98,037 New	98,037 $155,000
Q2 2023 Aug 10, 2023	SELL	$2.44 - $4.53 $176,817 - $328,270	-72,466 Reduced 37.32%	121,685 $315,000
Q1 2023 May 09, 2023	BUY	$3.72 - $5.4 $147,836 - $214,601	39,741 Added 25.74%	194,151 $792,000
Q4 2022 Feb 10, 2023	BUY	$3.41 - $12.93 $149,054 - $565,183	43,711 Added 39.49%	154,410 $775,000
Q3 2022 Nov 10, 2022	BUY	$12.59 - $17.67 $939,793 - $1.32 Million	74,646 Added 207.05%	110,699 $1.45 Million
Q2 2022 Aug 05, 2022	BUY	$10.58 - $17.5 $381,440 - $630,927	36,053 New	36,053 $462,000

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account